Patient group
Kinder, Jugendliche und Erwachsene ab einem Alter von 2 Monaten mit cholestatischem Pruritus bei Alagille-Syndrom
completed2023-01-15D series
Maralixibat
Alagille-Syndrom, ≥ 2 Monate
Open official case page ↗
- Brand
- Livmarli
- Manufacturer
- Mirum Pharmaceuticals Germany GmbH
G-BA action
final resolution
2023-07-06
Arzneimittel-Richtlinie/Anlage XII: Maralixibat (Alagille-Syndrom, ≥ 2 Monate)
Evidence-checked summary
The G-BA found a hint of non-quantifiable added benefit for Kinder, Jugendliche und Erwachsene ab einem Alter von 2 Monaten mit cholestatischem Pruritus bei Alagille-Syndrom. The G-BA issued a final resolution on 2023-07-06. The official page states that it took effect as follows: 06.07.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2023-05-22
101 parsed turns
Oral hearing: Maralixibat (Alagille-Syndrom, ≥ 2 Monate)
Official Wortprotokoll · 15 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.
G-BA decisions
Distinct actions and documents
2023-07-06
final resolution
Arzneimittel-Richtlinie/Anlage XII: Maralixibat (Alagille-Syndrom, ≥ 2 Monate)
The G-BA found a hint of non-quantifiable added benefit for Kinder, Jugendliche und Erwachsene ab einem Alter von 2 Monaten mit cholestatischem Pruritus bei Alagille-Syndrom. The G-BA issued a final resolution on 2023-07-06. The official page states that it took effect as follows: 06.07.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗gba assessment amendmentAmendment zur Nutzenbewertung des G-BAOpen ↗iqwig cost assessmentBewertung der Therapiekosten und Patientenzahlen IQWiGOpen ↗annex xii current versionMaralixibatOpen ↗gba assessmentNutzenbewertung G-BAOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗
Generic graph relations · 6
HAS ASSOCIATED DECISIONArzneimittel-Richtlinie/Anlage XII: Maralixibat (Alagille-Syndrom, ≥ 2 Monate)HAS HEARINGOral hearing: Maralixibat (Alagille-Syndrom, ≥ 2 Monate)OWNS DOCUMENTAmendment zur Nutzenbewertung des G-BAOWNS DOCUMENTBewertung der Therapiekosten und Patientenzahlen IQWiGOWNS DOCUMENTMaralixibatOWNS DOCUMENTNutzenbewertung G-BA